Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is a recent initial public offering that could come blessed with magical upside if its possibilities blossom into a positive reality. The company is targeting the commercialization of two…
Zynerba Pharmaceuticals saw its shares sink to a 52-week low after the firm announced results from its midstage trial evaluating cannabidiol gel for the treatment of knee pain due to osteoarthritis.
The rate alcohol use disorder, also known as alcoholism, rose by 49% in the first decade of the 2000s, according to a new study published in JAMA Psychiatry this month. Â One in eight American…
The July 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
One in 12 U.S. doctors received more than $46 million from 2013 to 2015 in payments from drug companies that were selling strong painkillers, according to a new study.
Acadia Pharmaceuticals reported its second-quarter financial results after the markets closed on Tuesday.
Mylan released its most recent quarterly earnings report before the markets opened on Wednesday. Unfortunately, the earnings and guidance weren't strong enough to hold up the firm and as a result shares hit a…
Valeant Pharmaceuticals reported mixed second-quarter financial results before the markets opened on Tuesday.
When FibroGen released its most recent quarterly results after the markets closed on Monday, its was not the most important news that broke.
Here are four biotech stocks for which the team of analysts at Jefferies, and analysts at other firms, see big upside potential from upcoming near-term drug study catalysts.
Horizon Pharma released a better than expected quarterly earnings report before the markets opened on Monday.
Although Agile Therapeutics stock is down year to date, it’s actually more or less doubled since January. So now might be the time to take some profit.
Zealand Pharma intends to price nearly 4 million shares at a price that will result in an initial public offering valued up to almost $98 million.
A blockbuster drug is about to get a chance to have even higher sales, as the FDA has expanded its approval of Imbruvica for the treatment of adult patients with chronic graft versus host…
